Ⓐ
PeptiBrief
Evidence Library
first_in_human_trial · 2021

First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension

Chen HH|Wan SH|Iyer SR|Harty GJ|Boerrigter G|Burnett JC Jr · Hypertension
moderateDOI · 10.1161/hypertensionaha.121.18025PMID · 34657445Verified
View source
Plain-English summary

MANP lowered blood pressure and increased natriuretic peptide pathway activity in an early clinical study.

Population
Adults with hypertension
Intervention
Subcutaneous MANP
Outcomes measured
Blood pressure|cGMP|Natriuresis|Safety
Key findings
Supported target engagement and blood-pressure lowering, requiring larger trials.
Limitations
Small early-phase study|Short follow-up|Specific engineered analogue|Does not generalise to all ANP analogues
Risk of bias
Moderate — first-in-human clinical pharmacology evidence.
Citation
Chen HH|Wan SH|Iyer SR|Harty GJ|Boerrigter G|Burnett JC Jr (2021). First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension. Hypertension. https://doi.org/10.1161/hypertensionaha.121.18025
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.